The United States Food and Drug Administration (FDA) has approved United States-based PTC Therapeutics Inc's. (NASDAQ: PTCT) Evrysdi (risdiplam), the first at-home, orally administered treatment for spinal muscular atrophy in adults and children two months and older, it was reported on Friday.
The product indicated clinical improvement in motor function and received developmental milestones across two trials in patients aged two months and above and across all levels of disease severity, including types one, two, and three spinal muscular atrophy.
Evrysdi was studied in a clinical trial program in spinal muscular atrophy with over 450 patients and subjects. It will be offered in the United States within two weeks for direct delivery to patients' homes via Accredo Health Group Inc, an Express Scripts specialty pharmacy.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT